Identifying the shared genes and KEGG pathways of Resolvin D1-targeted network and osteoarthritis using...

Area of Science:

• Biomedical Science
• Molecular Biology
• Pharmacology

Background:

• Osteoarthritis (OA) is a degenerative joint disease causing cartilage loss and reduced quality of life.
• The anti-inflammatory compound Resolvin D1 (RvD1) shows promise, but its mechanism in OA is not fully understood.
• Investigating RvD1's mechanism is crucial for developing novel OA treatments.

Purpose of the Study:

• To elucidate the potential mechanism of Resolvin D1 (RvD1) in osteoarthritis (OA) pathogenesis.
• To identify shared pathways between RvD1 targets and OA using bioinformatics analysis.
• To validate key molecular targets and signaling pathways in vitro.

Main Methods:

• Bioinformatic analysis of OA gene expression datasets (GSE82107, GSE55235, GSE55457, GSE169077).
• Identification of RvD1-targeted genes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways using STITCH.
• In vitro validation using IL-1β treated rat knee chondrocytes, including apoptosis assays, Western blotting, qRT-PCR, and ELISA.

Main Results:

• 27 shared KEGG pathways were identified between RvD1 targets and OA.
• RvD1 treatment significantly inhibited nuclear p65, p53, and p-JNK expression in IL-1β treated chondrocytes.
• RvD1 suppressed key signaling pathways including NF-κB, p53, MAPK/JNK, and PI3K-AKT.

Conclusions:

• Resolvin D1 (RvD1) demonstrates potential therapeutic effects against osteoarthritis (OA).
• RvD1 appears to exert its anti-osteoarthritic effects by modulating NF-κB, p53, MAPK/JNK, and PI3K-AKT signaling pathways.
• These findings suggest RvD1 as a potential treatment for OA by targeting key inflammatory and degenerative pathways.